Brokerages Set Nkarta, Inc. (NASDAQ:NKTX) Price Target at $13.50

Nkarta, Inc. (NASDAQ:NKTXGet Free Report) has been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $13.50.

Several research firms recently issued reports on NKTX. Stifel Nicolaus cut their price target on shares of Nkarta from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, August 14th. Wall Street Zen downgraded Nkarta from a “hold” rating to a “sell” rating in a research note on Friday, October 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Nkarta in a research note on Wednesday, October 8th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price objective on shares of Nkarta in a research report on Wednesday, August 13th.

Check Out Our Latest Analysis on NKTX

Hedge Funds Weigh In On Nkarta

Several hedge funds have recently bought and sold shares of NKTX. American Century Companies Inc. increased its position in shares of Nkarta by 6.5% in the first quarter. American Century Companies Inc. now owns 96,838 shares of the company’s stock valued at $178,000 after buying an additional 5,886 shares in the last quarter. CWM LLC increased its holdings in Nkarta by 23.4% during the 2nd quarter. CWM LLC now owns 34,758 shares of the company’s stock valued at $58,000 after acquiring an additional 6,601 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Nkarta by 4.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 231,081 shares of the company’s stock valued at $384,000 after acquiring an additional 8,968 shares in the last quarter. Geode Capital Management LLC increased its holdings in Nkarta by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,208,378 shares of the company’s stock valued at $2,006,000 after acquiring an additional 10,065 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in shares of Nkarta by 36.3% during the 1st quarter. Deutsche Bank AG now owns 58,812 shares of the company’s stock worth $108,000 after purchasing an additional 15,655 shares in the last quarter. 80.54% of the stock is owned by hedge funds and other institutional investors.

Nkarta Price Performance

Nkarta stock opened at $2.63 on Monday. Nkarta has a 12 month low of $1.31 and a 12 month high of $4.55. The business has a 50 day simple moving average of $2.14 and a 200-day simple moving average of $1.96. The stock has a market capitalization of $186.81 million, a PE ratio of -1.78 and a beta of 0.86.

Nkarta (NASDAQ:NKTXGet Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.06. As a group, equities research analysts anticipate that Nkarta will post -1.7 EPS for the current year.

About Nkarta

(Get Free Report)

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.

Read More

Analyst Recommendations for Nkarta (NASDAQ:NKTX)

Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.